BCL2

Across TCGA pan-cancer cohorts, BCL2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated BCL2 data layer compared with 22 for mass-spec protein and 4 for mutation status.

The strongest signal is observed in uterine corpus endometrial carcinoma (UCEC), where higher BCL2 mass-spec protein is associated with worse overall survival. In most high-consensus cancer types, elevated BCL2 expression acts as an unfavorable survival marker, although some lineages such as CCRCC and HNSC show a favorable association.

UCEC, CCRCC, and HNSC are the cancer types where BCL2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
UCEC	OS	Median	III,IV	0.433	1.000	.007	28	view →
CCRCC	DFS	Median	All	0.926	0.750	.012	15	view →
HNSC	OS	Median	All	0.862	0.564	.008	11	view →
GBM	DFS	Median	All	0.459	0.267	.042	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

BCL2–UCEC (OS)

Open the UCEC breakdown →